Within the market taxonomy, types of food‑grade omega‑3 are differentiated by source and molecular composition, each influencing cost structure and regulatory pathway. Fish‑oil concentrates, derived from anchovy, sardine, or mackerel, dominate with the highest EPA/DHA ratios and capture the bulk of supplement volume; their processing technology yields refined ethyl‑esters and triglyceride forms. Algal oil provides a plant‑based DHA‑rich alternative, increasingly adopted in infant formulas and vegan functional foods, and commands a price premium due to sustainable cultivation. Krill oil supplies phospholipid‑bound omega‑3, offering superior bioavailability but limited scalability, confining its market share to niche premium products. Marine phytoplankton extracts deliver a balanced EPA/DHA profile and are marketed for clinical nutrition, though regulatory acceptance varies across regions. Finally, synthetic omega‑3 (e.g., EPA‑only ethyl‑esters) serve specific therapeutic indications and are subject to distinct FDA pathways. The relative contribution of each type is shaped by raw‑material availability, consumer perception, and compliance requirements, collectively defining the overall market landscape.